peptide fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
== Bodybuilding titles == 1984 Mr Birmingham Novice, 1st 1985 World Games, 7th Heavyweights 1986 British Championships, 1st Heavyweight 1988 British Championships, 1st Heavyweight and overall 1990 Night of Champions, 2nd 1991 Night of Champions, 1st 1991 Mr. Olympia, 2nd 1991 English Grand Prix, 1st 1992 Mr. Olympia, 1st 1992 English Grand Prix, 1st 1993 Mr. Olympia, 1st 1994 Mr. Olympia, 1st 1994 Mr. Worldwide, 1st 1994 Spanish Grand Prix, 1st 1994 German Grand Prix, 1st 1994 English Grand Prix, 1st 1995 Mr. Olympia, 1st 1996 Mr. Olympia, 1st 1996 Spanish Grand Prix, 1st 1996 German Grand Prix, 1st 1996 English Grand Prix, 1st 1997 Mr. Olympia, 1st
Another consequence of the famine was the dramatic rise of the Marxist-Leninist-Maoist New People’s Army (NPA) presence on Negros island, with Bishop Fortich stating in 1985 that "the NPA has doubled in strength the last year, principally because of the poverty and hunger here."
Chlorosis, a condition where a plant cannot produce sufficient chlorophyll. A lack in copper, iron, manganese, or zinc can cause chlorosis. Boron deficiency, a condition where a plant's ability to reproduce, grow, and create stem cells is inhibited. Molybdenum deficiency, a condition where a buildup in nitrate because of a lack of nitrogenase production causes leaf yellowing, necrosis, and premature germination.
Sources: en.wikipedia.org
doi:10.1038/s41443-022-00636-7. PMID 36307732. Rushton, J.Philippe; Bogaert, Anthony F (1987). "Race differences in sexual behavior: Testing an evolutionary hypothesis". Journal of Research in Personality. 21 (4): 529–51. doi:10.1016/0092-6566(87)90038-9. Sutherland, Ronald S; Kogan, Barry A; Baskin, Laurence S; Mevorach, Robert A; Conte, Felix; Kaplan, Selna L; Grumbach, Melvin M (1996). "The Effect of Prepubertal Androgen Exposure on Adult Penile Length". The Journal of Urology. 156 (2): 783–7, discussion 787. doi:10.1016/S0022-5347(01)65814-2. PMID 8683783.
== History == The approach of reducing resistance during sets was described in the late 1940s by Henry Atkins, editor of Body Culture magazine, who called it the multi-poundage system. In the 1980s, drop sets formed part of Joe Weider's Weider System.
However, they are not true benign neoplasms (denoted by suffix ~oma), which are similar in appearance but very rare in the mouth. Fibrous epulis are fibroepithelial polyps located only on the gingivae. Pyogenic granuloma and pregnancy epulis are both vascular rather than fibrous epulides with more dilated blood vessels making them appear darker pink or red in colour, and soft. They may develop more fibrous as they mature. The pregnancy variant only appears in pregnancy, usually due to plaque and should resolve with better oral hygiene and at the end of the pregnancy if not. Pyogenic granuloma may occur elsewhere in the mouth such as the tongue and lips, but are not therefore epulides. Giant cell epulis, also known as peripheral giant cell granuloma, are like fibrous epulis and occur at the anterior interdental margin, the gum between the teeth at the front. They are more common in females. They are often soft round and deep red to purplish blue. It is important they are investigated to make are they are not true giant cell granuloma. Papilliary hyperplasia of the palate, or epulis fissaratum/denture-induced hyperplasia. The cause may be unknown, but there is an association with ill-fitting dentures resulting in irritation to the mucosa, usually by overextended flange, and with poor denture or oral hygiene. Oral thrush can be present but is not thought to be the cause.
Loss of consciousness can occur in myocardial infarctions due to inadequate blood flow to the brain and cardiogenic shock, and sudden death, frequently due to the development of ventricular fibrillation. When the brain was without oxygen for too long due to a myocardial infarction, coma and persistent vegetative state can occur. Cardiac arrest, and atypical symptoms such as palpitations, occur more frequently in females, the elderly, those with diabetes, in people who have just had surgery, and in critically ill patients.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.